Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DongKook Pharmaceutical Co., Ltd. (086450.KQ)
Seoul, KR
DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.57% | -3.92% | -19.34% | +0.24% | +12.40% | +22.07% | +25.30% | +33.48% | -23.06% | +54.22% | +320.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.1% ★ Q1'26: +12.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+7.9% Q1'26: +49.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.6% Q1'26: +4.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.4% Q1'26: +10.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.7% ★ Q1'26: +13.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.60× ★ Q1'26: 0.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
259.93B
est: 254.18B (+2.3%)
|
309.69B
est: 314.00B (-1.4%)
|
354.77B
est: 353.60B (+0.3%)
|
400.81B
est: 405.20B (-1.1%)
|
482.28B
est: 480.20B (+0.4%)
|
559.10B
est: 562.90B (-0.7%)
|
594.19B
est: 599.00B (-0.8%)
|
661.65B
est: 660.55B (+0.2%)
|
730.99B
est: 729.13B (+0.3%)
|
812.17B
est: 805.50B (+0.8%)
|
926.88B
est: 917.90B (+1.0%)
|
1.04T
1.04T – 1.04T
+13.3% YoY
|
1.17T
1.17T – 1.17T
+12.6% YoY
|
1.32T
1.32T – 1.32T
+12.6% YoY
|
1.48T
1.48T – 1.48T
+12.3% YoY
|
| EBITDA |
42.66B
est: 36.74B (+16.1%)
|
60.03B
est: 45.38B (+32.3%)
|
62.53B
est: 51.11B (+22.4%)
|
64.20B
est: 58.57B (+9.6%)
|
82.32B
est: 69.41B (+18.6%)
|
96.48B
est: 81.36B (+18.6%)
|
88.95B
est: 86.58B (+2.7%)
|
91.01B
est: 95.47B (-4.7%)
|
88.69B
est: 105.38B (-15.8%)
|
114.96B
est: 110.87B (+3.7%)
|
127.97B
est: 126.34B (+1.3%)
|
143.14B
143.14B – 143.14B
+13.3% YoY
|
161.12B
161.12B – 161.12B
+12.6% YoY
|
181.39B
181.39B – 181.39B
+12.6% YoY
|
203.69B
203.69B – 203.69B
+12.3% YoY
|
| EBIT |
37.02B
est: 29.16B (+27.0%)
|
54.29B
est: 36.02B (+50.7%)
|
55.20B
est: 40.56B (+36.1%)
|
63.52B
est: 46.48B (+36.7%)
|
77.01B
est: 55.09B (+39.8%)
|
81.38B
est: 64.57B (+26.0%)
|
71.61B
est: 68.71B (+4.2%)
|
71.83B
est: 75.78B (-5.2%)
|
67.60B
est: 83.64B (-19.2%)
|
86.68B
est: 85.72B (+1.1%)
|
96.47B
est: 97.69B (-1.2%)
|
110.68B
110.68B – 110.68B
+13.3% YoY
|
124.58B
124.58B – 124.58B
+12.6% YoY
|
140.26B
140.26B – 140.26B
+12.6% YoY
|
157.50B
157.50B – 157.50B
+12.3% YoY
|
| Net Income |
27.43B
est: 25.57B (+7.3%)
|
40.66B
est: 40.23B (+1.1%)
|
39.60B
est: 38.14B (+3.8%)
|
46.95B
est: 43.37B (+8.3%)
|
56.31B
est: 56.90B (-1.0%)
|
55.93B
est: 64.22B (-12.9%)
|
50.35B
est: 46.84B (+7.5%)
|
52.90B
est: 57.46B (-8.0%)
|
47.18B
est: 53.68B (-12.1%)
|
61.22B
est: 68.33B (-10.4%)
|
66.02B
est: 69.69B (-5.3%)
|
85.16B
85.16B – 85.16B
+22.2% YoY
|
94.89B
94.89B – 94.89B
+11.4% YoY
|
117.58B
117.58B – 117.58B
+23.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
68.98B
est: 96.33B (-28.4%)
|
86.20B
est: 119.00B (-27.6%)
|
103.05B
est: 134.01B (-23.1%)
|
117.85B
est: 153.56B (-23.3%)
|
144.86B
est: 181.99B (-20.4%)
|
231.53B
est: 213.33B (+8.5%)
|
256.86B
est: 227.01B (+13.1%)
|
207.67B
est: 250.33B (-17.0%)
|
311.21B
est: 276.33B (+12.6%)
|
250.88B
est: 308.97B (-18.8%)
|
405.12B
est: 352.08B (+15.1%)
|
398.90B
398.90B – 398.90B
+13.3% YoY
|
449.03B
449.03B – 449.03B
+12.6% YoY
|
505.51B
505.51B – 505.51B
+12.6% YoY
|
567.65B
567.65B – 567.65B
+12.3% YoY
|
| EPS |
623.99
est: 571.55 (+9.2%)
|
925.17
est: 899.20 (+2.9%)
|
901.10
est: 852.60 (+5.7%)
|
1,068.27
est: 969.40 (+10.2%)
|
1,281.33
est: 1,271.87 (+0.7%)
|
1,272.52
est: 1,435.50 (-11.4%)
|
1,145.56
est: 1,047.00 (+9.4%)
|
1,203.46
est: 1,284.50 (-6.3%)
|
1,064.00
est: 1,200.00 (-11.3%)
|
1,383.21
est: 1,526.50 (-9.4%)
|
1,487.00
est: 1,557.00 (-4.5%)
|
1,902.50
1,902.50 – 1,902.50
+22.2% YoY
|
2,120.00
2,120.00 – 2,120.00
+11.4% YoY
|
2,627.00
2,627.00 – 2,627.00
+23.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex MSCI Value 275290.KS | 0.95% | 214.6K | 0.30% |
| 2 | Kodex Healthcare 266420.KS | 0.25% | 114.8K | 0.09% |
| 3 | Kodex KOSDAQ 150 229200.KS | 0.21% | 6.35M | 0.25% |
| 4 | SAMSUNG KODEX KOSDAQ150 LEVERAGE ETF 233740.KS | 0.07% | 1.47M | 0.64% |
| 5 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.04% | 46.2K | 0.42% |
| 6 | Kodex MSCI Quality 275300.KS | 0.03% | 12.1K | 0.30% |
| 7 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 20.4K | 0.74% |
| 8 | Samsung Kodex Fn Growth ETF 325010.KS | 0.03% | 28.2K | 0.30% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 137.8K | 0.55% |
| 10 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 55.0K | 0.74% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bong-Ho Cho | Senior Managing Director of Sales | — | male |
| Gyu-Jin Lee | Managing Director of Factory Management | — | male |
| Hee-Soon Park | Senior Managing Director of Marketing | — | male |
| Heung-Ju Oh | Chief Executive Officer, Vice President & Director | — | male |
| Hong-Ki Kim | Director of Fin. | — | male |
| Je-Won Park | Senior Managing Director of Sales | — | male |
| Joon-Ho Song | Senior Managing Director of Strategic Planning | — | male |
| Se-Il Jeon | Senior Managing Director of Sales | — | male |
| Soon-Kang Hong | Senior Managing Director of PR | — | male |
| Young-Wook Lee | Chief Executive Officer, Pres & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 086450.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
